文献速递产科母胎医学

2023-2024年细小病毒B19感染激增是否与不良妊娠结局相关

Is parvovirus B19 infection upsurge in 2023-2024 associated with adverse pregnancy outcome?
PubMed 文献 · Ultrasound Obstet Gynecol · 2025-07-30

这项多中心回顾性队列研究比较了2023-2024年与2012-2022年孕产妇细小病毒B19感染后的围产结局。结果显示两组围产儿死亡率和复合不良围产结局率无显著差异,但2023-2024年队列中需要第二次宫内输血持续性胎儿贫血的比例显著更高。

要点

  • 2023-2024年队列需第二次宫内输血的持续性胎儿贫血比例显著高于2023年前队列(46.0% vs 19.4%,P=0.011)。
  • 两组围产儿死亡率(8.0% vs 6.4%,P=0.294)和复合不良围产结局率(21.7% vs 17.9%,P=0.395)无显著差异。
  • 2023-2024年队列中,就诊时胎儿水肿是围产儿死亡的独立预测因素(调整OR 10.91,95%CI 1.89-63.07,P=0.007)。

核心结论

  • 研究期间孕产妇细小病毒B19感染后的围产儿死亡率和复合不良围产结局率与2023年前历史队列相似,但2023-2024年病例需要更多产前干预,包括需要超过一次宫内输血。

研究设计与样本

  • 多中心回顾性队列研究,比较2023年前(2012-2022年)与2023-2024年孕产妇确诊细小病毒B19感染后的围产结局。
  • 排除记录不完整、持续妊娠、合并巨细胞病毒或EB病毒感染、原有结构或遗传异常、免疫性胎儿水肿或母体血清学结果不支持细小病毒B19感染的病例。
  • 最终纳入2023年前140例和2023-2024年175例进行分析。

主要发现

  • 就诊时胎儿水肿率两组相似(2023年前22.9% vs 2023-2024年23.4%,P=0.905)。
  • 围产儿死亡率(2023年前6.4% vs 2023-2024年8.0%,P=0.294)和复合不良围产结局率(2023年前17.9% vs 2023-2024年21.7%,P=0.395)组间无显著差异。
  • 需要第二次宫内输血的持续性胎儿贫血比例在2023-2024年队列显著更高(46.0% vs 19.4%,P=0.011)。
  • 2023-2024年队列中,就诊时胎儿水肿是围产儿死亡的独立预测因素(调整OR 10.91,95%CI 1.89-63.07,P=0.007)。

关键数值与推荐

  • 围产儿死亡定义:≥20周妊娠的宫内胎儿死亡或分娩后≤28天的新生儿死亡。
  • 复合不良围产结局定义:存在一种或多种不良结局,包括围产儿死亡、<20周妊娠丢失、新发结构异常和因细小病毒相关疾病终止妊娠。

临床怎么用

  • 早期识别和监测对于减轻孕产妇细小病毒B19感染后的不良围产结局仍然至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A surge in parvovirus B19 infections has been reported in 2023-2024 across Europe and the USA, raising concerns about the associated perinatal risks. The aim of this study was to compare perinatal outcomes following maternal parvovirus B19 infection during the 2023-2024 period with those from a pre-2023 cohort. METHODS: This multicenter, retrospective cohort study compared perinatal outcomes in women with maternal parvovirus B19 infection according to whether infection occurred pre-2023 (2012-2022) or between 2023 and 2024. Pregnant women with confirmed parvovirus B19 infection were eligible for inclusion. Cases were excluded if they had incomplete records, an ongoing pregnancy, coinfection with cytomegalovirus or Epstein-Barr virus, pre-existing structural or genetic abnormality, immune fetal hydrops or a maternal serology result not indicative of parvovirus B19 infection. The primary outcome was perinatal mortality, which was defined as intrauterine fetal death ≥ 20 weeks' gestation or neonatal death ≤ 28 days after delivery. The secondary outcomes were persistent fetal anemia requiring more than one intrauterine transfusion (IUT) and a composite adverse perinatal outcome (CAPO), defined as the presence of one or more adverse outcomes, including perinatal mortality, pregnancy loss < 20 weeks, new-onset structural anomaly and termination of pregnancy owing to parvovirus-related morbidity. Differences between the two groups were assessed using standard statistical tests, and a generalized linear mixed model was used to identify predictors of perinatal mortality in the 2023-2024 cohort. RESULTS: Following exclusions, 140 cases from pre-2023 and 175 cases from 2023-2024 were analyzed. The rate of fetal hydrops at presentation was similar across the two groups (22.9% in pre-2023 vs 23.4% in 2023-2024; P = 0.905). The rates of perinatal mortality (6.4% in pre-2023 vs 8.0% in 2023-2024; P = 0.294) and CAPO (17.9% in pre-2023 vs 21.7% in 2023-2024; P = 0.395) were not significantly different between groups, but the proportion of fetuses with persistent fetal anemia requiring a second IUT was significantly higher in the 2023-2024 cohort (46.0% vs 19.4%; P = 0.011). For the 2023-2024 cohort, fetal hydrops at presentation was an independent predictor of perinatal mortality (adjusted odds ratio, 10.91 (95% CI, 1.89-63.07); P = 0.007). CONCLUSION: In this multicenter collaboration, we report perinatal outcomes following maternal parvovirus B19 infection during the recent upsurge and compare them with those of a historical cohort. Although perinatal mortality and CAPO rates were similar between cohorts, cases in the recent surge (2023-2024) required more prenatal interventions, including the need for more than one IUT. Early identification and monitoring remain essential to mitigate adverse perinatal outcomes following maternal parvovirus B19 infection. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Prasad S, Khalil A, Yinon Y, et al. Is parvovirus B19 infection upsurge in 2023-2024 associated with adverse pregnancy outcome? Ultrasound Obstet Gynecol. 2025. PMID: 40737630. doi:10.1002/uog.29301

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。